Have Insiders Sold Silk Road Medical Shares Recently?
Have Insiders Sold Silk Road Medical Shares Recently?
Anyone interested in Silk Road Medical, Inc (NASDAQ:SILK) should probably be aware that the CFO & COO, Lucas Buchanan, recently divested US$170k worth of shares in the company, at an average price of US$17.17 each. On the bright side, that sale was only 6.0% of their holding, so we doubt it's very meaningful, on its own.
任何对丝路医疗公司(纳斯达克股票代码:SILK)感兴趣的人都应该知道,首席财务官兼首席运营官卢卡斯·布坎南最近以平均每股17.17美元的价格剥离了该公司价值17万美元的股份。好的一面是,那次出售仅占他们持股量的6.0%,因此我们怀疑这本身是否有意义。
The Last 12 Months Of Insider Transactions At Silk Road Medical
丝路医疗过去12个月的内幕交易
Notably, that recent sale by Lucas Buchanan is the biggest insider sale of Silk Road Medical shares that we've seen in the last year. That means that an insider was selling shares at around the current price of US$16.40. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. In this case, the big sale took place at around the current price, so it's not too bad (but it's still not a positive).
值得注意的是,卢卡斯·布坎南最近的出售是我们在去年看到的最大规模的丝绸之路医疗股票内幕出售。这意味着一位内部人士正在以当前的16.40美元左右的价格出售股票。尽管内幕抛售是负面的,但对我们来说,如果以较低的价格出售股票,则负面影响更大。在这种情况下,大甩卖是在当前价格左右进行的,因此还不错(但仍然不是积极的)。
Silk Road Medical insiders didn't buy any shares over the last year. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!
去年,丝路医疗内部人士没有购买任何股票。您可以看到下图所示的去年的内幕交易(公司和个人)。通过点击下面的图表,你可以看到每笔内幕交易的确切细节!
![insider-trading-volume](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240309/0-053522721b3443ba76c771de259150e7-0-9ba50c0b78b42a75900a9d0cb1bce3c8.png/big)
If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.
如果你像我一样,那么你不会想错过这份业内人士正在收购的成长型公司的免费名单。
Does Silk Road Medical Boast High Insider Ownership?
丝绸之路医疗是否拥有很高的内部所有权?
Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Silk Road Medical insiders own about US$13m worth of shares. That equates to 2.1% of the company. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.
测试公司领导者与其他股东之间一致性的另一种方法是查看他们拥有多少股份。通常,内部人士的所有权越高,内部人士长期建立公司的可能性就越大。丝路医疗内部人士拥有价值约1300万美元的股票。这相当于该公司的2.1%。当然,我们在其他地方看到了更高的内部所有权水平,但这些持股足以表明内部人士与其他股东之间的一致性。
So What Does This Data Suggest About Silk Road Medical Insiders?
那么这些数据对丝绸之路医学内部人士有什么启示呢?
Insiders haven't bought Silk Road Medical stock in the last three months, but there was some selling. And there weren't any purchases to give us comfort, over the last year. Insiders own shares, but we're still pretty cautious, given the history of sales. We'd practice some caution before buying! So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. At Simply Wall St, we found 2 warning signs for Silk Road Medical that deserve your attention before buying any shares.
内部人士在过去三个月中没有买入丝绸之路医疗的股票,但出现了一些抛售。在过去的一年里,没有任何能让我们感到安慰的购买。内部人士拥有股票,但考虑到销售历史,我们仍然相当谨慎。购买前我们会谨慎行事!因此,这些内幕交易可以帮助我们建立有关股票的论点,但也值得了解该公司面临的风险。在Simply Wall St,我们发现了丝路医疗的两个警告信号,在购买任何股票之前,值得你注意。
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.
如果你想看看另一家公司——一家财务状况可能优越的公司——那么千万不要错过这份免费的股本回报率高、债务低的有趣公司的名单。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
就本文而言,内部人士是指向相关监管机构报告其交易的个人。我们目前只考虑公开市场交易和私下处置的直接利益,不包括衍生品交易或间接权益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。